01474nas a2200265   4500000000100000008004100001260001700042653001500059653001000074653001200084653001200096653001400108653001100122653001200133653000900145653001700154100001300171700001900184245007000203300001000273490000700283050003200290520087200322022001401194       1986                            d  c1986 Jul-Sep10aAcedapsone10aAdult10aAnimals10aDapsone10aHalf-Life10aHumans10aleprosy10aMice10aTime Factors1 aGeorge J1 aBalakrishnan S00aBlood dapsone levels in leprosy patients treated with acedapsone.  a401-60 v58  aInfolep Library - available3 a<p>The metabolism of the repository drug acedapsone (DADDS,4,4'-diacetyldiaminodiphenyl sulfone) was studied in 15 individuals receiving 225 mg of DADDS, intramuscularly for a period of 75 days. Plasma levels of DDS were determined on the 2nd, 7th, 15th, 30th, 60th and 75th day after administration of the drug by spectrophoto-fluorometric technique. The mean peak levels of DDS (85.36 ng/ml) were noticed on 7th day followed by a gradual decrease in DDS concentration. The mean half-life level (44.53 ng/ml) of DDS were observed around the 15th day. The mean DDS level for the entire period of observation after one dose was 41.95 ng/ml. On the 75th day, the DDS level reached the minimum value of 14.76 ng/ml which was still about 5 times more than the minimal inhibitory concentration (MIC) level of DDS against M. leprae (3 ng/ml). The results are discussed.</p>  a0254-9395